The company distinguishes its approach by moving beyond the mutation-focused strategies currently employed by industry leaders. While existing individualized neoantigen therapies rely primarily on mutations, BreakBio uses its proprietary AI to identify a broader spectrum of targets, including cancer-associated non-mutated proteins like embryonic antigens. This expanded targeting capability aims to address both high-mutational cancers, such as melanoma, and low-mutational solid tumors, including colorectal cancer.

By integrating patient-specific DNA and RNA sequencing with deep AI analysis, BreakBio intends to deliver higher efficacy per patient. The firm plans to combine its individualized peptide-based medicines with approved cancer therapies to maximize treatment outcomes. With COO and CFO Kim Nancarrow overseeing the transition, the company aims to move from its current development phase into human clinical trials within three months.